BIU 3.0: Ulm Biocenter goes into the future with a new research partnership!

BIU 3.0: Ulm Biocenter goes into the future with a new research partnership!

The "Boehringer Ingelheim Ulm University Biocenter" (BIU) starts the third phase in 2025 and thus continues the successful cooperation between the University of Ulm and the pharmaceutical company Boehringer Ingelheim. This partnership, which started in 2011, has the ambitious goal of specifically accelerating new therapeutic approaches through the combination of basic research and clinical application. Professor Pamela Fischer-Posovszky, the new spokeswoman for the BIU, emphasizes the importance of cooperation for future-oriented research and patient care.

In the coming years, exciting projects for cardiovascular, metabolic and lung diseases will be developed, with both main and pilot projects being promoted. The previous phase, BIU 2.0, already shone with 23 scientific publications and promising research results, including the discovery of a microrna that could be important for diabetes treatment, as well as new findings on lung fibrosis. The first projects start in January 2025, whereby up to 100,000 euros per main project could be available. Further information on this topic offers The article on www.ulm-news.de .